Drug · DIN 02112795
SALOFALK
ALSO KNOWN AS MESALAMINE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since July 16, 2024; first marketed December 31, 1995.
- Drug Identification Number (DIN)
- 02112795
- Company (DIN owner)
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Suspension
- Route
- Rectal
- Therapeutic class (ATC)
- Mesalazine A07EC02
- Class
- Human
- Record last updated
- August 17, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| MESALAZINE | 2 G | 60 G |
Notices of Compliance
Health Canada approvals that name this DIN.
- November 16, 2022: NOC 29481New Drug Submission (NDS) · Administrative: Change in Product Ownership
- December 1, 2011: NOC 12825New Drug Submission (NDS) · Manufacturer Name Change
- July 15, 1994: NOC 5390New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “salofalk”. A notice may cover another product or only some lots: read it to see what it covers.
- SALOFALK 500mg: tablets may show black spots due to the oxidation of the active ingredient.April 24, 2025 · Drugs · Product quality · Type II
Other DINs named SALOFALK
- DIN 02112760 · Marketed
- DIN 02112787 · Marketed
- DIN 02112809 · Marketed
- DIN 02242146 · Marketed